MY200586A - Pharmaceutical composition in the form of a chewable tablet of diosmin or a flavonoid fraction - Google Patents
Pharmaceutical composition in the form of a chewable tablet of diosmin or a flavonoid fractionInfo
- Publication number
- MY200586A MY200586A MYPI2021000084A MYPI2021000084A MY200586A MY 200586 A MY200586 A MY 200586A MY PI2021000084 A MYPI2021000084 A MY PI2021000084A MY PI2021000084 A MYPI2021000084 A MY PI2021000084A MY 200586 A MY200586 A MY 200586A
- Authority
- MY
- Malaysia
- Prior art keywords
- pharmaceutical composition
- diosmin
- chewable tablet
- flavonoid fraction
- micronised
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A pharmaceutical composition in the form of a chewable tablet containing a high dose of micronised diosmin. This pharmaceutical composition comprises a percentage of micronised diosmin of from 20% to 80% of the total mass of the pharmaceutical composition. This pharmaceutical composition is used in the treatment of venous insufficiency and haemorrhoidal attack.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1856769A FR3083980B1 (en) | 2018-07-20 | 2018-07-20 | PHARMACEUTICAL COMPOSITION IN THE FORM OF A CHEWABLE TABLET OF DIOSMINE OR A FLAVONOIC FRACTION |
| PCT/EP2019/069498 WO2020016408A1 (en) | 2018-07-20 | 2019-07-19 | Pharmaceutical composition in the form of a chewable tablet of diosmin or of a flavonoid moiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY200586A true MY200586A (en) | 2024-01-04 |
Family
ID=65243687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2021000084A MY200586A (en) | 2018-07-20 | 2019-07-19 | Pharmaceutical composition in the form of a chewable tablet of diosmin or a flavonoid fraction |
Country Status (36)
| Country | Link |
|---|---|
| EP (2) | EP3823588B1 (en) |
| KR (1) | KR20210034036A (en) |
| CN (2) | CN112423735A (en) |
| AR (1) | AR117612A1 (en) |
| AU (1) | AU2019306315B2 (en) |
| BR (1) | BR112021000440A2 (en) |
| CA (1) | CA3106495C (en) |
| CL (1) | CL2021000083A1 (en) |
| CO (1) | CO2021000115A2 (en) |
| CR (1) | CR20210023A (en) |
| DK (1) | DK3823588T3 (en) |
| EA (1) | EA202190269A1 (en) |
| EC (1) | ECSP21001232A (en) |
| ES (1) | ES2991941T3 (en) |
| FI (1) | FI3823588T3 (en) |
| FR (1) | FR3083980B1 (en) |
| GE (1) | GEP20237532B (en) |
| HR (1) | HRP20250037T1 (en) |
| HU (1) | HUE069700T2 (en) |
| JO (1) | JOP20210003A1 (en) |
| LT (1) | LT3823588T (en) |
| MA (1) | MA53159B1 (en) |
| MD (1) | MD3823588T2 (en) |
| MX (1) | MX2021000763A (en) |
| MY (1) | MY200586A (en) |
| NI (1) | NI202100002A (en) |
| PE (1) | PE20210929A1 (en) |
| PH (1) | PH12021550037A1 (en) |
| PL (1) | PL3823588T3 (en) |
| PT (1) | PT3823588T (en) |
| RS (1) | RS66288B1 (en) |
| SG (1) | SG11202100181YA (en) |
| SI (1) | SI3823588T1 (en) |
| TW (1) | TWI831808B (en) |
| UA (1) | UA128677C2 (en) |
| WO (1) | WO2020016408A1 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2661610B1 (en) * | 1990-05-02 | 1994-09-30 | Rhone Poulenc Sante | NOVEL LYOPHILIZED FORM OF DIOSMINE AND ITS PREPARATION. |
| FR2661830B1 (en) * | 1990-05-11 | 1992-09-04 | Corbiere Jerome | NOVEL PHARMACEUTICAL COMPOSITIONS BASED ON FLAVONOSIDE. |
| FR2726469B1 (en) * | 1994-11-08 | 1996-12-13 | Adir | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF FLAVONOIDS |
| FR2845597B1 (en) | 2002-10-11 | 2005-03-11 | Innothera Lab Sa | DRY ORAL FORMULATION CONTAINING DIOSMINE AS A PHARMACEUTICAL FORM OF A TABLET TO BE CROQUERED |
| ITMI20050517A1 (en) | 2005-03-30 | 2006-09-30 | Therapicon Srl | PHARMACEUTICAL COMPOSITION OF A TYPICAL MICROCRYSTALLINE FRACTION OF FLAVONOIDS |
| FR2999934B1 (en) * | 2012-12-21 | 2015-02-20 | Servier Lab | PHARMACEUTICAL COMPOSITION IN THE FORM OF AN ORAL SUSPENSION COMPRISING A FLAVONOIC FRACTION AND XANTHAN GUM |
-
2018
- 2018-07-20 FR FR1856769A patent/FR3083980B1/en active Active
-
2019
- 2019-07-19 RS RS20241369A patent/RS66288B1/en unknown
- 2019-07-19 MA MA53159A patent/MA53159B1/en unknown
- 2019-07-19 CN CN201980047436.7A patent/CN112423735A/en active Pending
- 2019-07-19 WO PCT/EP2019/069498 patent/WO2020016408A1/en not_active Ceased
- 2019-07-19 SG SG11202100181YA patent/SG11202100181YA/en unknown
- 2019-07-19 TW TW108125532A patent/TWI831808B/en active
- 2019-07-19 AU AU2019306315A patent/AU2019306315B2/en active Active
- 2019-07-19 PE PE2021000077A patent/PE20210929A1/en unknown
- 2019-07-19 MY MYPI2021000084A patent/MY200586A/en unknown
- 2019-07-19 JO JOP/2021/0003A patent/JOP20210003A1/en unknown
- 2019-07-19 GE GEAP202315564A patent/GEP20237532B/en unknown
- 2019-07-19 SI SI201930858T patent/SI3823588T1/en unknown
- 2019-07-19 FI FIEP19742363.5T patent/FI3823588T3/en active
- 2019-07-19 ES ES19742363T patent/ES2991941T3/en active Active
- 2019-07-19 UA UAA202100556A patent/UA128677C2/en unknown
- 2019-07-19 PT PT197423635T patent/PT3823588T/en unknown
- 2019-07-19 LT LTEPPCT/EP2019/069498T patent/LT3823588T/en unknown
- 2019-07-19 KR KR1020217004706A patent/KR20210034036A/en not_active Ceased
- 2019-07-19 BR BR112021000440-8A patent/BR112021000440A2/en unknown
- 2019-07-19 MX MX2021000763A patent/MX2021000763A/en unknown
- 2019-07-19 CA CA3106495A patent/CA3106495C/en active Active
- 2019-07-19 PL PL19742363.5T patent/PL3823588T3/en unknown
- 2019-07-19 HR HRP20250037TT patent/HRP20250037T1/en unknown
- 2019-07-19 EP EP19742363.5A patent/EP3823588B1/en active Active
- 2019-07-19 MD MDE20210479T patent/MD3823588T2/en unknown
- 2019-07-19 DK DK19742363.5T patent/DK3823588T3/en active
- 2019-07-19 HU HUE19742363A patent/HUE069700T2/en unknown
- 2019-07-19 CN CN202411465581.6A patent/CN119345141A/en active Pending
- 2019-07-19 AR ARP190102031A patent/AR117612A1/en unknown
- 2019-07-19 EP EP24208148.7A patent/EP4473977A3/en active Pending
- 2019-07-19 CR CR20210023A patent/CR20210023A/en unknown
- 2019-07-19 EA EA202190269A patent/EA202190269A1/en unknown
-
2021
- 2021-01-07 PH PH12021550037A patent/PH12021550037A1/en unknown
- 2021-01-08 CO CONC2021/0000115A patent/CO2021000115A2/en unknown
- 2021-01-08 NI NI202100002A patent/NI202100002A/en unknown
- 2021-01-08 EC ECSENADI20211232A patent/ECSP21001232A/en unknown
- 2021-01-12 CL CL2021000083A patent/CL2021000083A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX394961B (en) | COMPOSITIONS FOR USE IN THE TREATMENT OF DISEASES RELATED TO INTERLEUKIN 6 | |
| PH12018502634A1 (en) | Topical compositions of apremilast | |
| EP4230623A3 (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| BR112018005454A2 (en) | administration of deuterated cftr enhancers | |
| BR112015022197A8 (en) | use of a compound for the manufacture of a medicament or pharmaceutical composition for treating cataplexy | |
| PE20180411A1 (en) | PHARMACEUTICAL FORMULATIONS INCLUDING TENOFOVIR AND EMTRICITABIN | |
| EP4403213A3 (en) | Methods for reducing cardiovascular risk | |
| WO2018111315A8 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES | |
| NZ754962A (en) | Compositions and methods for treating, ameliorating and preventing h. pylori infections | |
| MX2020010300A (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof. | |
| DOP2016000254A (en) | PHARMECEUTIC FORMULATIONS OF PAN-RAF QUINASE INHIBITOR, PROCEDURES FOR THEIR PREPARATION, AND METHODS OF USE. | |
| BR112016001544A8 (en) | pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an anti-inflammatory agent | |
| MY207469A (en) | Therapeutic compounds | |
| CY1125769T1 (en) | PHARMACEUTICAL COMBINATIONS CONTAINING A HISTENO DEACETYLATION INHIBITOR AND A BCL-2 INHIBITOR AND METHODS OF USING THEM | |
| MX2021006156A (en) | Compounds useful in hiv therapy. | |
| MX2021002916A (en) | PIRPHENIDONE ENRICHED WITH DEUTERIUM AND METHODS FOR ITS USE. | |
| BR112021011368A2 (en) | Ketoprofen cocrystal, compositions comprising the same, process for their production and uses thereof | |
| CL2018000430A1 (en) | Hydroxytriazine compound and related medical use. | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| SG10201908089VA (en) | Novel dosing regimens of celgosivir for the treatment of dengue | |
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| BR112018072298A2 (en) | treatment of Zika virus infections using alpha-glucosidase inhibitors | |
| MX2023010545A (en) | Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof. | |
| MY200586A (en) | Pharmaceutical composition in the form of a chewable tablet of diosmin or a flavonoid fraction | |
| BR112015023368A2 (en) | Vitamin B12 deficiency treatment method |